Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors in the secondary prevention of cardiovascular disease: Forecasting the incremental benefits of preventing coronary and cerebrovascular events

Archives of Internal Medicine

Volumn 159, Issue 6, 1999, Pages 593-600

  Grover, Steven A ^a,b,c   Coupal, Louis ^a   Paquet, Steeve ^a   Zowall, Hanna ^a  

^a Ctr Anal of Cost Effective Care   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN;

ADULT; AGED; ANGIOPLASTY; ARTICLE; ARTIFICIAL HEART PACEMAKER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH CARE COST; HEART ARRHYTHMIA; HEART CATHETERIZATION; HEART REINFARCTION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SECONDARY PREVENTION; STROKE; SURVIVAL; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; ANTILIPEMIC AGENTS; CANADA; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE EXPECTANCY; MALE; MIDDLE AGED; RECURRENCE; RISK; SCANDINAVIA; SENSITIVITY AND SPECIFICITY; SIMVASTATIN;

EID: 0033594134     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.6.593     Document Type: Article

References (39)

1. Reeder BA, Chockalingam A, Dagenais GR, et al. Heart Disease and Stroke in Canada, 1995. Ottawa, Ontario: Heart and Stroke Foundation of Canada; 1995.
2. Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
3. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335:1001-1009.
4. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation. 1995;92:2419-2425.
5. Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention [published correction appears in Arch Intern Med. 1998;158: 1228]. Arch Intern Med. 1998;158:655-662.
6. Johannesson M, Jönsson B, Kjekshus J, et al, for the Scandinavian Simvastatin Survival Study Group. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 1997;336: 332-336.
7. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation. 1996;93:1796-1802.
8. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 1991;265:1145-1151.
9. Ashraf T, Hay JW, Pitt B, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1996;78:409-414.
10. Jönsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J. 1996;17:1001-1007.
11. Central Patient Registry and Coordinating Center for the Lipid Research Clinics. Reference Manual for the Lipid Research Clinics Prevalence Study. Vols 1 and 2. Chapel Hill: Dept of Biostatistics, University of North Carolina; 1974.
12. Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Prevalence Study. Circulation. 1979;60:427-439.
13. Heiss G, Tamir I, Davis CE, et al. Lipoprotein-cholesterol distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation. 1980;61:302-315.
14. Lipid Research Clinics Program. Manual of Laboratory Operations: Lipid and Lipoprotein Analysis. Vol 1. Bethesda, Md: National Heart, Lung, and Blood Institute, National Institutes of Health, US Dept of Health, Education and Welfare; 1974. Publication NIH 75-628.
15. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
16. Grover SA, Coupal L, Hu XP. Identifying adults at increased risk of coronary disease: how well do the current cholesterol guidelines work? JAMA. 1995;274: 801-806.
17. Kannel WB, Wolf PA, Garrison RJ. Survival following initial cardiovascular events: 30 year follow-up. In. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Bethesda, Md: National Heart, Lung and Blood Institute, National Institutes of Health, US Dept of Health and Human Services; 1988: sect 35. Publication NIH 88-2969.
18. Resource Intensity Weights: Summary of Methodology, 1996/97. Ottawa, Ontario: Canadian Institute for Health Information; 1996.
19. Manuel des Médecins Spécialistes RAMQ. Québec: Régie de l'assurance-maladie du Québec; 1996.
20. Manuel des Médecins Omnipraticiens RAMQ/Manuel des Médecins Spécialistes RAMQ. Québec: Régie de l'assurance-maladie du Québec; 1996.
21. Ontario Ministry of Health. Schedule of Benefits: Physician Services, 1992. Toronto: Ontario Ministry of Health; 1992.
22. Statistics Canada. Canadian Economic Observer: Statistical Summary. Ottawa, Ontario: Statistics Canada; 1997. Catalogue 11-010-XPB.
23. Bélanger L, Bolduc M, Noël M. Relative importance of after-effects, environment and socio-economic factors on the social integration of stroke victims. Int J Rehabil Res. 1988;11:251-260.
24. Statistics Canada. Hospital Statistics: Preliminary Annual Report, 1994-95. Ottawa, Ontario: Health Statistics Division; 1996. Catalogue 83-241-XMB.
25. Statistics Canada. Residential Care Facilities, 1993-94. Ottawa, Ontario: Health Statistics Division; 1996. Catalogue 83-237-XMB.
26. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke: design, organization, and baseline results. Stroke. 1988;19:1203-1210.
27. Feinberg WM, Albers GW, Barnett HJM, et al. Guidelines for the management of transient ischemic attacks: Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks of the Stroke Council of the American Heart Association. Stroke. 1994;25:1320-1335.
28. IMS of Canada, Ltd. Canadian Compuscript, January - December 1996. Pointe Claire, Quebec: IMS of Canada, Ltd; 1996.
29. Adams HP Jr, Brott TG, Crowell RM, et al. Guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 1994;25:1901-1914.
30. Sherman DG, Dyken ML Jr, Fisher M, Gent M, Harrison M, Hart RG. Antithrombotic therapy for cerebrovascular disorders. Chest. 1992;102(suppl):529S-537S.
31. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276: 1253-1258.
32. Crouse JR III, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor mono-therapy and stroke prevention. Arch Intern Med. 1997;157:1305-1310.
33. Fuchs VR, Hahn JS. How does Canada do it? a comparison of expenditures for physicians' services in the United States and Canada. N Engl J Med. 1990;323: 884-890.
34. Goldman L, Garber AM, Grover SA, Hlatky MA. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events: Task Force 6: cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol. 1996;27:1020-1030.
35. Abbott RD, McGee D. The probability of developing certain cardiovascular disease in eight years at specified values of some characteristics. In: Kannel WB, Wolf PA, Garrison RJ, eds. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Washington, DC: US Dept of Health, Education, and Welfare; 1987:sect37. Publication NIH 87-2284.
36. Grover SA, Palmer CS, Coupal L. Serum lipid screening to identify high-risk individuals for coronary death: the results of the Lipid Research Clinics prevalence cohort. Arch Intern Med. 1994;154:679-684.
37. Rouleau JL, Moyé LA, Pfeffer MA, et al, for the SAVE Investigators. A comparison of management patterns after acute myocardial infarction in Canada and the United States. N Engl J Med. 1993;328:779-784.
38. Mark DB, Naylor CD, Hlatky MA, et al. Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med. 1994;331:1130-1135.
39. Pilote L, Racine N, Hlatky MA. Differences in the treatment of myocardial infarction in the United States and Canada. Arch Intern Med. 1994;154:1090-1096.